ライフサイエンスコーパス: mucosa-associated lymphoid tissue

1 d has been implicated in B cell lymphomas of mucosa-associated lymphoid tissue.

2 /memory lymphocytes to the intestine and the mucosa-associated lymphoid tissue.

3 f gastric adenocarcinoma and lymphoma of the mucosa-associated lymphoid tissue.

4 the spectrum of low-grade B-cell lymphoma of mucosa-associated lymphoid tissue.

5 s of mammalian mucosal surfaces exhibiting a mucosa-associated lymphoid tissue.

6 ulate the risk of lymphomagenesis in gastric mucosa-associated lymphoid tissue.

7 nfection, most likely through M cells of the mucosa-associated lymphoid tissue.

8 ts with extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.

9 reased IgD CSR exclusively within B cells of mucosa-associated lymphoid tissues.

10 ow trout and that it resembles other teleost mucosa-associated lymphoid tissues.

11 eir interaction directs lymphocyte homing to mucosa-associated lymphoid tissues.

12 uded caspase recruitment domain 11 (CARD11), mucosa-associated lymphoid tissue 1 (MALT1) for combined

13 Herein, we found that mucosa-associated lymphoid tissue 1 (MALT1) is involved

14 ly 50% of patients with gastric lymphomas of mucosa-associated lymphoid tissue, although long-term fo

15 The probable source of persistent virus is mucosa-associated lymphoid tissue, although the molecula

16 Nasal mucosa-associated lymphoid tissue and submandibular lymp

17 NK-22 cells are also found in mouse mucosa-associated lymphoid tissues and appear in the sma

18 he specialized regions where antigens access mucosa-associated lymphoid tissue, are sites where HIV-1

19 ll lymphomas (DLBCLs), including DLBCLs with mucosa-associated lymphoid tissue (DLBCL[MALT]) and with

20 tered to mimic those normally present within mucosa-associated lymphoid tissues (e.g., Peyer's patche

21 , five extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue, five anaplastic large

22 of apoptotic cells was also observed in the mucosa-associated lymphoid tissue lining the trachea and

23 uces remission in most patients with gastric mucosa-associated lymphoid tissue lymphoma (GML) that is

24 r risk factor for gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma (MALT).

25 Mucosa-associated lymphoid tissue lymphoma (MALToma) is

26 ptake), including 4 patients with coexisting mucosa-associated lymphoid tissue lymphoma (maximal stan

27 lymphoma (n = 6), plasmacytoma (n = 5), and mucosa-associated lymphoid tissue lymphoma (n = 3) were

28 iduals also had an increased risk of stomach mucosa-associated lymphoid tissue lymphoma (SIR, 5.99; 9

29 h the development of both gastric cancer and mucosa-associated lymphoid tissue lymphoma in humans is

30 heilmannii" is associated with gastritis and mucosa-associated lymphoid tissue lymphoma in people.

31 h studies on the diagnosis and management of mucosa-associated lymphoid tissue lymphoma published ear

32 tations of TNFAIP3 have been observed in the mucosa-associated lymphoid tissue lymphoma subtype frequ

33 plex with B-cell CLL/lymphoma 10 (BCL10) and mucosa-associated lymphoid tissue lymphoma translocation

34 ated with B-cell CLL/lymphoma 10 (BCL10) and mucosa-associated lymphoid tissue lymphoma translocation

35 nic lymphocytic leukemia/lymphoma 10 (BCL10)-mucosa-associated lymphoid tissue lymphoma translocation

36 composed of B cell CLL/lymphoma 10 (BCL10), mucosa-associated lymphoid tissue lymphoma translocation

37 The mucosa-associated lymphoid tissue lymphoma translocation

38 ase (MAGUK) protein 1/B-cell CLL-lymphoma 10/mucosa-associated lymphoid tissue lymphoma translocation

39 Brd4, phosphoinositide-3-kinase, annexin A1, mucosa-associated lymphoid tissue lymphoma translocation

40 ical factor in peptic ulcer disease, gastric mucosa-associated lymphoid tissue lymphoma, and gastric

41 , including gastric and duodenal ulceration, mucosa-associated lymphoid tissue lymphoma, and gastric

42 bserved in diffuse large B-cell lymphoma and mucosa-associated lymphoid tissue lymphoma, being associ

43 ts of distinct chromosomal translocations in mucosa-associated lymphoid tissue lymphoma, cooperate in

44 able outcome; and in patients with low grade mucosa-associated lymphoid tissue lymphoma, eradication

45 Among cases of conjunctival mucosa-associated lymphoid tissue lymphoma, human herpes

46 of diffuse large B-cell lymphoma (DLBCL) and mucosa-associated lymphoid tissue lymphoma, lymphomas re

47 ymphoma (MCL), marginal zone lymphoma (MZL), mucosa-associated lymphoid tissue lymphoma, lymphoplasma

48 In early gastric cancer and gastric mucosa-associated lymphoid tissue lymphoma, the best ava

49 tudied, gastrointestinal lymphoma is gastric mucosa-associated lymphoid tissue lymphoma, which is a p

50 can cause the development of gastric B cell mucosa-associated lymphoid tissue lymphoma, yet little i

51 otrimers with B-cell lymphoma 10 (BCL10) and mucosa-associated lymphoid tissue lymphoma-translocation

52 ion studies were performed with T cells from mucosa-associated lymphoid tissue lymphoma-translocation

53 c ulcer disease, gastric cancer, and gastric mucosa-associated lymphoid tissue lymphoma.

54 ic gastritis, gastric carcinoma, and gastric mucosa-associated lymphoid tissue lymphoma.

55 results included 3 additional patients with mucosa-associated lymphoid tissue lymphoma.

56 as even higher (77%) among pSS patients with mucosa-associated lymphoid tissue lymphoma.

57 o consensus on standard initial treatment of mucosa-associated lymphoid tissue lymphoma.

58 association with gastric cancer and gastric mucosa-associated lymphoid tissue lymphoma.

59 er DLBCLs and never in Burkitt's lymphoma or mucosa-associated lymphoid tissue lymphoma.

60 pylori eradication in patients with gastric mucosa-associated lymphoid tissue lymphoma.

61 treatment planning in patients with gastric mucosa-associated lymphoid tissue lymphoma.

62 c ulcer disease, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma.

63 nsistent with their potential to evolve into mucosa-associated lymphoid tissue lymphoma.

64 onship to gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue lymphoma.(2) In the la

65 lorambucil demonstrated superior efficacy in mucosa-associated lymphoid tissue lymphoma; however, imp

66 3) Extranodal mucosa associated lymphoid tissue lymphomas are easily c

67 lymphomas (2.3%) were the most frequent, and mucosa-associated lymphoid tissue lymphomas (5.8%).

68 This is important as early-stage gastric mucosa-associated lymphoid tissue lymphomas can be manag

69 Further, the development of ocular adnexal mucosa-associated lymphoid tissue lymphomas has been ass

70 trasound, in the diagnosis and management of mucosa-associated lymphoid tissue lymphomas of the stoma

71 understanding of the genetic alterations in mucosa-associated lymphoid tissue lymphomas, including v

72 urkitt's lymphoma, but was observed in 9% of mucosa-associated lymphoid tissue lymphomas.

73 gastric ulcers, gastric adenocarcinomas, and mucosa-associated lymphoid tissue lymphomas.

74 Salivary gland mucosa associated lymphoid tissue (MALT) type lymphomas

75 Lymphomas arising in mucosa-associated lymphoid tissue (MALT) are indolent B-

76 l marginal zone (MZ) B-cell lymphomas of the mucosa-associated lymphoid tissue (MALT) arise from lymp

77 Marginal zone mucosa-associated lymphoid tissue (MALT) B-cell lymphoma

78 ow-grade, small lymphocytic lymphomas of the mucosa-associated lymphoid tissue (MALT) have recently b

79 yphlocolitis, associated epithelial defects, mucosa-associated lymphoid tissue (MALT) hyperplasia, an

80 Gastric lymphoma of mucosa-associated lymphoid tissue (MALT) is related to H

81 59 = 42%) (germinal center cell origin) and mucosa-associated lymphoid tissue (MALT) lymphoma (19 of

82 ice has been described as a model of gastric mucosa-associated lymphoid tissue (MALT) lymphoma (GML).

83 ression profiling (GEP) of primary pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma (n = 3

84 While primary ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (POAML

85 ulture who previously received rituximab for mucosa-associated lymphoid tissue (MALT) lymphoma and st

86 The tendency for gastric mucosa-associated lymphoid tissue (MALT) lymphoma cells

87 Since the first description of mucosa-associated lymphoid tissue (MALT) lymphoma in 198

88 jogren's syndrome (SS) developed a low-grade mucosa-associated lymphoid tissue (MALT) lymphoma in the

89 reated by the recurrent t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma induce

90 The development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma is dep

91 Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is ind

92 Mucosa-associated lymphoid tissue (MALT) lymphoma is the

93 Mucosa-associated lymphoid tissue (MALT) lymphoma is the

94 Gastric lymphoma resembling gastric mucosa-associated lymphoid tissue (MALT) lymphoma linked

95 Mucosa-associated lymphoid tissue (MALT) lymphoma of the

96 stopathology and immunohistochemistry showed mucosa-associated lymphoid tissue (MALT) lymphoma with i

97 as chronic gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue (MALT) lymphoma, and g

98 ude active or inactive peptic ulcer disease, mucosa-associated lymphoid tissue (MALT) lymphoma, as we

99 he standard of care in patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma, much

100 ved in the t(1;14)(p22;q32) translocation of mucosa-associated lymphoid tissue (MALT) lymphoma.

101 is directly involved in t(1;14)(p22;q32) of mucosa-associated lymphoid tissue (MALT) lymphoma.

102 which is the most frequent translocation in mucosa-associated lymphoid tissue (MALT) lymphoma.

103 11;18)(q21;q21) chromosomal translocation in mucosa-associated lymphoid tissue (MALT) lymphoma.

104 ns involving the MALT1 gene are hallmarks of mucosa-associated lymphoid tissue (MALT) lymphoma.

105 ion resulted in the best OS in patients with mucosa-associated lymphoid tissue (MALT) lymphomas (HR =

106 The pathogenesis of mucosa-associated lymphoid tissue (MALT) lymphomas is as

107 Mucosa-associated lymphoid tissue (MALT) lymphomas most

108 phoma specimens, as follows: 8 of 120 (6.7%) mucosa-associated lymphoid tissue (MALT) lymphomas, 4 of

109 ning protein involved in the etiology of the mucosa-associated lymphoid tissue (MALT) lymphomas, has

110 idy are recurrent chromosomal aberrations in mucosa-associated lymphoid tissue (MALT) lymphomas.

111 munoglobulin heavy chain (IgH) locus in some mucosa-associated lymphoid tissue (MALT) lymphomas.

112 Mucosa-associated lymphoid tissue (MALT) may accumulate

113 developments concerning gastric lymphomas of mucosa-associated lymphoid tissue (MALT) origin, ranging

114 Low-grade lesions nearly always arise from mucosa-associated lymphoid tissue (MALT) secondary to ch

115 utes can allow antigens to interact with the mucosa-associated lymphoid tissue (MALT) to induce both

116 nodal marginal zone B-cell lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) type is listed

117 Salivary gland mucosa-associated lymphoid tissue (MALT) type lymphomas

118 nexal lymphoma, is marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type.

119 a case of primary gastric B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) with a secondar

120 ncurrent gastric and intestinal lymphomas of mucosa-associated lymphoid tissue (MALT), the clonal rel

121 -cell lymphomas (DLBCLs) without features of mucosa-associated lymphoid tissue (MALT), the pure (de n

122 vestigation revealed that she had an orbital mucosa-associated lymphoid tissue (MALT)-type B cell lym

123 Although it is well established that mucosa-associated lymphoid tissue (MALT)-type lymphomas

124 ed were extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT).

125 ces for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT).

126 d expression of a number of genes within the mucosa-associated lymphoid tissue (MALT).

127 eligible patients (339 with WM, 37 with non-mucosa-associated lymphoid tissue marginal zone lymphoma

128 spores, phagocytosis of spores in the nasal mucosa-associated lymphoid tissue (NALT) and lungs by ma

129 the cervical lymph nodes (CLN) and the nasal mucosa-associated lymphoid tissue (NALT) and tested for

130 ections have two portals of entry, the nasal mucosa-associated lymphoid tissue (NALT) and the lumen o

131 eported that GAS preferentially target nasal mucosa-associated lymphoid tissue (NALT) in mice, a tiss

132 g of iFT from the nasal passage to the nasal mucosa-associated lymphoid tissue (NALT).

133 g inoculation, but not in the adjacent nasal mucosa-associated lymphoid tissue (NALT).

134 lar lymphoma, diffuse large B-cell lymphoma, mucosa-associated lymphoid tissue non-Hodgkin lymphoma,

135 calization, the chief immunoglobulins of all mucosa-associated lymphoid tissue operate under the guid

136 l lymphoma, angiotropic large cell lymphoma, mucosa-associated lymphoid tissue, primary pulmonary T-c

137 omains of c-IAP2 with the paracaspase/MALT1 (mucosa-associated lymphoid tissue) protein, a critical m

138 nversion (RT-QuIC) assay by using recto-anal mucosa-associated lymphoid tissue (RAMALT) biopsy specim

139 ced conversion (RT-QuIC) assay of recto-anal mucosa-associated lymphoid tissue (RAMALT) biopsy specim

140 The examination of rectoanal mucosa-associated lymphoid tissue (RAMALT) biopsy specim

141 Functional analysis of the gastrointestinal mucosa-associated lymphoid tissue revealed increased sig

142 ization of a human NK cell subset located in mucosa-associated lymphoid tissues, such as tonsils and

143 icular-associated epithelium (FAE) overlying mucosa-associated lymphoid tissues, their density increa

144 Gastric B-cell lymphoma of mucosa-associated lymphoid tissue type is closely linked

145 hocyte responses, is aberrantly expressed in mucosa-associated lymphoid tissue-type marginal zone (MZ